IFNG and systemic lupus erythematosus: Targeting the cytokine/growth factor pathway—which is important for plasma cell generation and the development of SLE—has been supported by several studies targeting the IL-6 pathway and receptors for the treatment of SLE (47); however, targeting IL-6 and IFN-γ failed to produce significant renal effects in either case.